| Literature DB >> 23687496 |
Teruyuki Takahashi1, Masato Tamura, Kenji Miki, Mai Yamaguchi, Akira Kanno, Satoshi Nunomura, Chisei Ra, Takashi Tamiya, Satoshi Kamei, Toshiaki Takasu.
Abstract
BACKGROUND: Myelitis is one of the rarest neurological complications of the varicella zoster virus (VZV) infection. Focal muscle weakness with or without sensory disturbance occurs in approximately 5% of the cases after acute VZV infection, with complete recovery in 50-70%. CASEEntities:
Keywords: Antibody index; Enzyme immunoassay; Myelitis; Nested polymerase chain reaction assay; Varicella zoster virus
Year: 2013 PMID: 23687496 PMCID: PMC3656678 DOI: 10.1159/000350714
Source DB: PubMed Journal: Case Rep Neurol ISSN: 1662-680X
Sequences of primers for original nested PCR assay
| Target | Assay | Type | Sequence | Nucleotide position | Product size | |
|---|---|---|---|---|---|---|
| ORF-29 of wild VZV DNA1 | First-step PCR | outer forward primer | WZ-F1 | 5′-GTCCTAGAGGAGGTTTTATCTGC-3′ | 53942–53964 | 172 |
| (=single PCR) | outer reverse primer | WZ-R1 | 5′-AATGCCATATGTTGTGCTCGAGC-3′ | 54113–54091 | ||
| Second-step PCR | inner forward primer | WZ-F2 | 5′-TCCCTCGTCGGGAAATCGAGAAA-3′ | 53976–53998 | 88 | |
| (=nested PCR) | inner reverse primer | WZ-R2 | 5′-TATGGCTAATTGAACCATGGCCC-3′ | 54063–54041 | ||
GenBank accession no. 1 NC_001348.1 (X04370).
Original nested PCR assay conditions
| First-step PCR | Second-step PCR | |||
|---|---|---|---|---|
| Initial denaturing | 96.0°C: 3 min | Initial denaturing | 96.0°C: 3 min | |
| Amplification | 35 cycles | Amplification | 25 cycles | |
| Denaturing | 95.0°C: 30 s | Denaturing | 94.0°C: 30 s | |
| Annealing | 60.0°C: 30 s | Annealing | 55.0°C: 30 s | |
| Extension | 72.0°C: 1 min | Extension | 72.0°C: 1 min | |
| Final extension | 72.0°C: 10 min | Final extension | 72.0°C: 10 min |
Fig. 1a–c Spinal cord MRI findings. a Sagittal T2-weighted MRI (TR 3809, TE110) of the cervical spine (c) in patient 1. A high-signal-intensity lesion at the cervical spinal nerve 2 is shown. b Sagittal T2-weighted MRI (TR 3797, TE 110) of thoracic spine in patient 2. c Axial T2-weighted MRI (TR 539, TE 18) of thoracic spine in patient 2. A high-signal-intensity lesion at Th 3–4 is shown. d, e Nested PCR assay results for the CSF specimen collected on admission. d Patient 1, e patient 2. * Positive result. Lane 1: molecular weight marker, lane 2: internal control (human β-globin: 196 bp), lane 3: negative control (clinically isolated Staphylococcus aureus DNA), lane 4: case, lane 5: positive control (172 bp), lane 6: negative control, lane 7: case, lane 8: positive control (88 bp), lanes 3–5: single-PCR assay results, lanes 6–8: nested PCR results. As a positive control, the original plasmid into which a DNA fragment (172 bp) of the ORF-29 gene had been inserted was prepared. The nucleotide sequence of the inserted DNA fragment was confirmed by direct sequencing in both strands. The extracted DNA specimens from clinically isolated Staphylococcus aureus were used as a negative control. In addition, as an internal control, a pair of primers specific to the human β-globin gene (GenBank accession no. L48217) was prepared. The 196-bp human β-globin gene fragment as an internal control was amplified in another tube under the same assay conditions. In conventional single-PCR assay, a weak 172-bp band was only shown at lane 4 for patient 1. In contrast, the nested PCR assay demonstrated clearly positive 88-bp bands at lane 7 for both patients.
Summary of clinical study results in 2 patients during clinical course
| Patient 1 | CSF collection date | March 11, 2010 (on admission) | March 18 | March 25 | April 5 | April 20 | May 7 |
|---|---|---|---|---|---|---|---|
| Basal CSF findings | RBC, /µl | 2 | 1 | 0 | 1 | 0 | 0 |
| Cell (WBC), /µl | 156 | 113 | 105 | 50 | 25 | 8 | |
| M:P | 460:9 | 330:8 | 310:4 | 147:2 | 35:2 | 23:5 | |
| Protein, mg/dl | 155 | 138 | 107 | 70 | 56 | 48 | |
| Glucose, mg/dl | 51 | 50 | 61 | 61 | 48 | 52 | |
| Bacterial culture | – | – | – | – | – | – | |
| CSF IgG, mg/dl | 34.0 | 13.5 | 19.1 | 25.4 | 22.9 | N.D. | |
| Serum IgG, mg/dl | 1,115 | 1,143 | 972 | 684 | 783 | N.D. | |
| Commercial single-PCR assays (SRL Inc.) | VZV DNA | – | – | – | – | – | N.D. |
| HSV1 DNA | – | – | – | N.D. | N.D. | N.D. | |
| CMV DNA | – | – | N.D. | N.D. | N.D. | N.D. | |
| Original nested PCR assay | VZV DNA | + | – | – | – | – | N.D. |
| IgM EIA value (negative <0.8 positive >1.2) | Anti-VZV | ||||||
| CSF | 0.51 | 0.18 | 0.11 | 0.09 | N.D. | N.D. | |
| Serum | 1.26* | 0.78 | 0.82 | 0.74 | N.D. | N.D. | |
| Anti-HSV1 | |||||||
| CSF | 0.62 | 0.28 | 0.18 | N.D. | N.D. | N.D. | |
| Serum | 0.71 | 0.76 | 0.68 | N.D. | N.D. | N.D. | |
| Anti-CMV | |||||||
| CSF | 0.44 | 0.16 | N.D. | N.D. | N.D. | N.D. | |
| Serum | 0.34 | 0.24 | N.D. | N.D. | N.D. | N.D. | |
| IgG EIA value (CSF: negative <0.20 positive >0.40 Serum: negative <2.0 positive >4.0) | Anti-VZV | ||||||
| CSF | >12.8* | >12.8* | 11.6* | 8.73* | 7.48* | N.D. | |
| Serum | >128.0* | >128.0* | 105.2* | 75.4* | 66.3* | N.D. | |
| Antibody index | 3.28† | 8.47† | 5.62† | 3.12† | 3.86† | N.D. | |
| Anti-HSV1 | |||||||
| CSF | 8.8* | 7.8* | 6.8* | 3.5* | N.D. | N.D. | |
| Serum | >128.0* | 125.4* | 98.7* | 68.3* | N.D. | N.D. | |
| Antibody index | 3.28† | 5.27† | 3.51† | 1.37 | N.D. | N.D. | |
| Anti-CMV | |||||||
| CSF | 2.5* | 2.0* | 0.8* | N.D. | N.D. | N.D. | |
| Serum | 84.5* | 85.4* | 52.6* | N.D. | N.D. | N.D. | |
| Antibody index | 0.97 | 1.98 | 0.77 | N.D. | N.D. | N.D. | |
| Patient 2 | CSF collection date | April 13, 2011 (On admission) | April 20 | April 27 | May 11 | May 20 | |
| Basal CSF findings | RBC, /µl | 0 | 2 | 1 | 0 | 1 | |
| Cell (WBC), /µl | 110 | 20 | 10 | 4 | 3 | ||
| M:P | 320:11 | 30:1 | 16:1 | 9:1 | 11:2 | ||
| Protein, mg/dl | 93 | 61 | 29 | 33 | 24 | ||
| Glucose, mg/dl | 51 | 61 | 62 | 58 | 54 | ||
| Bacterial culture | – | – | – | – | – | ||
| CSF IgG, mg/dl | 22.5 | 9.0 | 5.1 | 6.2 | N.D. | ||
| Serum IgG, mg/dl | 1,855 | 1,603 | 1,268 | 1,044 | N.D. | ||
| Commercial single-PCR assays (SRL Inc.) | VZV-DNA | – | – | – | – | N.D. | |
| HSV1-DNA | – | – | – | N.D. | N.D. | ||
| CMV-DNA | – | – | N.D. | N.D. | N.D. | ||
| Original nested PCR assay | VZV-DNA | + | – | – | – | N.D. | |
| IgM EIA value (negative <0.8 positive >1.2) | Anti-VZV | ||||||
| CSF | 0.24 | 0.15 | 0.09 | 0.11 | N.D. | ||
| Serum | 0.18 | 0.16 | 0.15 | 0.16 | N.D. | ||
| Anti-HSV1 | |||||||
| CSF | 0.30 | 0.31 | 0.60 | N.D. | N.D. | ||
| Serum | 0.46 | 0.50 | 0.57 | N.D. | N.D. | ||
| Anti-CMV | |||||||
| CSF | 0.20 | 0.22 | N.D. | N.D. | N.D. | ||
| Serum | 0.37 | 0.38 | N.D. | N.D. | N.D. | ||
| IgG EIA value (CSF: negative <0.20 positive >0.40 Serum: negative <2.0 positive >4.0) | Anti-VZV | ||||||
| CSF | >12.8* | >12.8* | 10.3* | 7.8* | N.D. | ||
| Serum | >128* | 124.2* | 115.7* | 85.8* | N.D. | ||
| Antibody index | 8.24† | 18.35† | 22.13† | 12.67† | N.D. | ||
| Anti-HSV1 | |||||||
| CSF | 7.3* | 6.3* | 8.3* | 6.8* | N.D. | ||
| Serum | >128* | 99.6* | >128* | 105.4* | N.D. | ||
| Antibody index | 4.70† | 11.26† | 16.12† | 10.8† | N.D. | ||
| Anti-CMV | |||||||
| CSF | 2.0* | 2.0* | N.D. | N.D. | N.D. | ||
| Serum | 32* | 18.2* | N.D. | N.D. | N.D. | ||
| Antibody index | 5.15† | 19.57† | N.D. | N.D. | N.D. | ||
M = Mononuclear cell; P = polymorphonuclear cell; N.D. = not done. *positive EIA value; †positive antibody index.